Program
anumigilimab
Also written as “CSL324” and “Anumigilimab”.
Its studies are mostly in Anemia, Sickle Cell · COVID-19, led by CSL.
Furthest: phase 2, since Aug 18, 20204 company-led studies, 1 open or runningNext primary completion: Aug 15, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 41 open or running | phase 2since Aug 18, 2020 | Aug 18, 2020 | Aug 15, 2028phase 2 · NCT07224360 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2020First study: phase 2 study in COVID-19First studyNCT04519424
- Sep 25, 2020Phase 1 study in HealthyNCT04570267 · 32 enrolled · Australia
- Dec 8, 2022Phase 1 study in Healthy VolunteersNCT05653713 · 40 enrolled · Germany
- Oct 31, 2025Phase 2 study in Anemia, Sickle CellNCT07224360 · 63 planned · United States, Belgium, France and more
Ahead
- Aug 15, 2028Primary completion: phase 2 study in Anemia, Sickle CellNCT07224360
TargetBeta
CSF3R →read by rule
“Granulocyte colony stimulating factor receptor antagonist”ChEMBL 37, by rule
Other programs on CSF3R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pegfilgrastimrule | Amgen | phase 4 | 52 |
| Filgrastimrule | Pfizer | phase 4 | 33 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07224360Anemia, Sickle Cell · United States, Belgium, France and more | 2 | Recruiting | Aug 15, 2028 | 63 |
| NCT05653713Healthy Volunteers · Germany | 1 | Completed | Jul 21, 2023 | 40 |
| NCT04570267Healthy · Australia | 1 | Completed | Nov 17, 2021 | 32 |
| NCT04519424COVID-19 | 2 | Withdrawn | Apr 2021 | 0 |
How it is read
Names in the registry
- “CSL324”, 3 entries
- “Anumigilimab”, 1 entry
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.